Skip to main navigation Skip to search Skip to main content

Abstract

Ischemic diseases including myocardial infarction (MI) and limb ischemia are some of the greatest causes of morbidity and mortality worldwide. Cell therapy is a potential treatment but is usually limited by poor survival and retention of donor cells injected at the target site. Since much of the therapeutic effects occur via cell-secreted paracrine factors, including extracellular vesicles (EVs), we developed a porous material for cell encapsulation which would improve donor cell retention and survival, while allowing EV secretion. Human donor cardiac mesenchymal cells were used as a model therapeutic cell and the encapsulation system could sustain three-dimensional cell growth and secretion of therapeutic factors. Secretion of EVs and protective growth factors were increased by encapsulation, and secreted EVs had hypoxia-protective, pro-angiogenic activities in in vitro assays. In a mouse model of limb ischemia the implant improved angiogenesis and blood flow, and in an MI model the system preserved ejection fraction %. In both instances, the encapsulation system greatly extended donor cell retention and survival compared to directly injected cells. This system represents a promising therapy for ischemic diseases and could be adapted for treatment of other diseases in the future.
Original languageEnglish
Pages (from-to)879-892
Number of pages14
JournalJournal of Controlled Release
Volume352
DOIs
Publication statusPublished - Dec 2022

Keywords

  • Cardiac patch
  • Cell encapsulation
  • Cell therapy
  • Exosome
  • Extracellular vesicle
  • Ischemic disease
  • Limb ischemia
  • Myocardial infarction

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint

Dive into the research topics of 'Porous scaffold for mesenchymal cell encapsulation and exosome-based therapy of ischemic diseases'. Together they form a unique fingerprint.

Cite this